Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 58c
Get Alerts JAZZ Hot Sheet
Price: $244.54 -2.61%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
CHA, EDXC, YAYO, More
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
CHA, EDXC, YAYO, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $4.21, $0.58 better than the analyst estimate of $3.63. Revenue for the quarter came in at $892.88 million versus the consensus estimate of $865.88 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2022 EPS of $16.00-$17.00, versus the consensus of $17.47.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $310 at Needham
- BW LPG Limited (BWLP) Reports Q1 EPS of $0.79
- Autodesk (ADSK) Tops Q2 EPS by 18c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share